End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 NZD | -4.46% | -7.08% | -31.02% |
Apr. 22 | New Zealand Shares Jumps on Business Optimism; Ryman Healthcare CEO Resigns | MT |
Apr. 21 | Ryman Healthcare Group CEO Resigns | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.02% | 1.65B | B | ||
-28.69% | 85.35B | B- | ||
+14.32% | 81.95B | C+ | ||
+9.37% | 28.99B | C+ | ||
-11.43% | 16.98B | B | ||
-0.36% | 16.85B | A- | ||
-0.24% | 15.35B | A- | ||
+4.32% | 12.42B | A- | ||
+33.40% | 12.19B | B- | ||
-31.40% | 11.89B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RYM Stock
- Ratings Ryman Healthcare Limited